News Pharnext SCA

Equities

ALPHA

FR001400N1P4

Real-time Euronext Paris Other stock markets 03:58:45 2024-04-24 am EDT			5-day change	1st Jan Change
0.14 ^EUR	-7.47%		-9.09%	-93.00%

Mar. 06	Pharnext: listing suspended pending further update	CF
Feb. 21	Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharnext Sca : Pharnext takes full stock of its operating, strategic and financial situation	Mar. 11	AT
Pharnext: listing suspended pending further update	Mar. 06	CF
Pharnext : Présentation corporate de Pharnext	Mar. 05	PU
Pharnext Sca : Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A	Feb. 28	AT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	Feb. 21
Pharnext SA announced that it has received ?41.188458 million in funding	Jan. 30	CI
Pharnext launches drastic cost-cutting plan	Jan. 17	CF
Pharnext Unveils Cost Reduction Plan, to Continue Development of Neurological Disorder Drug	Jan. 17	MT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	Jan. 17	AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	Jan. 17	AT
Pharnext: registration dossiers prepared for Charcot disease	Dec. 19	CF
Pharnext Sca : Pharnext intends to prepare registration and marketing authorization dossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A	Dec. 19	AT
Pharnext: share price falls after disappointing clinical study	Dec. 11	CF
Pharnext Sa : Pharnext reports topline results from the pivotal Phase III clinical trial (PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A	Dec. 11	AT
Pharnext : Document AMF CP. 2023E941731	Dec. 08	PU
Pharnext : Document AMF CP. 2023E941502	Dec. 07	PU
Pharnext SA announced that it expects to receive ?1.5 million in funding	Dec. 04	CI
Pharnext: phase III study data frozen	Dec. 04	CF
Pharnext Sa : Pharnext announces database lock for PXT3003 pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A, last step before topline results publication	Dec. 04	AT
Pharnext : Document AMF CP. 2023E940554	Dec. 01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pharnext SCA

Equities

ALPHA

FR001400N1P4

Summary

Filters